For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.

Research Papers

A curated index of peer-reviewed literature on peptides, with plain-language summaries. All links open to the original source (PubMed, journals, preprints). Research Stack does not host any papers.

Summaries are paraphrased for accessibility. Always read the original paper in full before drawing conclusions. Most studies are preclinical (animal models) unless stated otherwise.

Gastrointestinal

Current Pharmaceutical Design2011Sikiric P, Seiwerth S, Rucman R, et al.

Comprehensive review of BPC-157's gastroprotective mechanisms. Covers protection from ethanol, NSAIDs, and stress-induced ulcers in rodent models. Documents NO-pathway involvement and cytoprotective effects across multiple GI tissues.

Musculoskeletal

Journal of Applied Physiology2003Staresinic M, Sebecic B, Patrlj L, et al.

Rodent study demonstrating accelerated Achilles tendon healing following BPC-157 treatment. Histology showed improved tendon organization and mechanical strength versus control. Established BPC-157 as a promising soft tissue repair agent.

Growth Hormone

Journal of Clinical Endocrinology & Metabolism2005Jetté L, et al.

Phase I/II human trial demonstrating that CJC-1295 DAC produces sustained GH and IGF-1 elevation for up to 6 days after a single dose. Dose-dependent increases observed. Well tolerated with minimal adverse effects across all dose groups.

Metabolic / GLP-1

New England Journal of Medicine2021Wilding JPH, Batterham RL, Calanna S, et al.

Landmark RCT (n=1961) showing that weekly 2.4mg semaglutide resulted in mean body weight reduction of 14.9% vs. 2.4% placebo over 68 weeks. Significant improvements in cardiometabolic risk factors. Established semaglutide as a major advance in obesity pharmacotherapy.

Cardiovascular

New England Journal of Medicine2023Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.

Large-scale cardiovascular outcomes trial (n=17,604) demonstrating semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease. First GLP-1 agonist trial to show cardiovascular benefit independent of diabetes status.

Dermatology / Anti-Aging

Biomolecules2015Pickart L, Vasquez-Soltero JM, Margolina A.

Review article summarizing GHK-Cu's role in skin repair. Covers upregulation of collagen I, II, and III synthesis, stimulation of wound contraction, and broad gene regulatory effects affecting over 4,000 human genes. Discusses topical and systemic applications.